Immutep's Efti Shows 30.9-Month Survival in Lung Cancer, TACTI-004 Analysis Reveals Immune Profile Shift
IMMP sits 43% above its 52-week low of $0.293.
Summary
Immutep reported mature overall survival data from the INSIGHT-003 Phase I trial of efti plus Keytruda and chemo in first-line non-squamous NSCLC. Median OS reached 30.9 months in the overall population and in the low/no PD-L1 subgroup, comparing favorably to the 22-month benchmark from a registrational trial. The company also provided an update on the failed TACTI-004 Phase III trial, revealing a markedly different immune activation profile in efti-treated patients versus prior studies, which may explain the futility outcome. The root cause analysis is ongoing with additional results expected in Q3 2026. This follows the May 2026 discontinuation of TACTI-004 and the $10M payment obligation, but the strong INSIGHT-003 survival signal in a hard-to-treat population could support a path forward for efti. Merck's Keytruda is the combination partner, but Immutep is the primary beneficiary of the data.
At the time of this announcement, IMMP was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.2M. The 52-week trading range was $0.29 to $3.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.